Successfully treated multicentric Castleman's disease with renal thrombotic microangiopathy using rituximab and corticosteroid

Clin Nephrol. 2011 Feb;75(2):165-70. doi: 10.5414/cn106491.

Abstract

Thrombotic microangiopathy (TMA) is a rare renal complication accompanied with Castleman's disease. We report the first case of TMA combined plasma cell type multicentric Castleman's disease (MCD) which was successfully treated with rituximab and corticosteroid. A previously healthy 60-year-old Korean man was admitted due to acute renal failure, thrombocytopenia, and multiple lymphadenopathies. The result of lymph node biopsy was plasma cell type Castleman's disease and TMA was revealed by kidney biopsy. After treatment with rituximab, prednisolone and temporary hemodialysis, complete remission was achieved. The combination of corticosteroid and rituximab was associated with improvement for this patient.

Publication types

  • Case Reports

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use*
  • Biopsy
  • Castleman Disease / complications
  • Castleman Disease / diagnosis
  • Castleman Disease / drug therapy*
  • Drug Therapy, Combination
  • Humans
  • Immunologic Factors / therapeutic use*
  • Kidney / pathology
  • Kidney Diseases / diagnosis
  • Kidney Diseases / drug therapy*
  • Kidney Diseases / etiology
  • Lymph Nodes / pathology
  • Male
  • Middle Aged
  • Renal Dialysis
  • Rituximab
  • Severity of Illness Index
  • Thrombotic Microangiopathies / diagnosis
  • Thrombotic Microangiopathies / drug therapy*
  • Thrombotic Microangiopathies / etiology
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Adrenal Cortex Hormones
  • Antibodies, Monoclonal, Murine-Derived
  • Immunologic Factors
  • Rituximab